Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience

Cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplant (allo-HSCT) is mainly due to an increase of latent viremia in previously exposed patients. Furthermore, CMV reactivation in this setting has a significant impact on patient survival. Traditional approach to CMV re...

Full description

Bibliographic Details
Main Authors: Jessica Gill, Davide Stella, Irene Dogliotti, Chiara Dellacasa, Luisa Giaccone, Alessandro Busca
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Hemato
Subjects:
allogeneic hematopoietic stem cell transplant
CMV
pre-emptive therapy
letermovir
Online Access:https://www.mdpi.com/2673-6357/4/2/13

Internet

https://www.mdpi.com/2673-6357/4/2/13

Similar Items